This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...

Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent...

This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward...

Label changes affect how balsalazide is prescribed and monitored for people with ulcerative colitis. The update highlights safety risks—especially kidney, liver, and hypersensitivity concerns—and reinforces age- and...

This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...

Children with IBD and neurodevelopmental disorders may face different perioperative courses after colectomy — notably longer preoperative stays, greater need for nutritional support, and higher risk of postoperative...

This study suggests a new preclinical approach to help the gut lining heal in ulcerative colitis by targeting macrophage metabolism (myeloid AMPK) rather than directly treating epithelial cells. That could matter for...

This paper describes a novel nanozyme that reduced oxidative stress and inflammation in preclinical models of colitis and enteropathic arthritis — a possible future therapeutic approach that targets ROS in inflamed gut...

A national pediatric IBD registry from Colombia summarizes diagnosis age, disease types, treatment patterns (including rising biologic use), and outcomes—information that can inform families and clinicians about regional...

Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunity, inflammation...

Low muscle mass before ileocolic resection appears linked to higher short-term surgical complications and higher rates of endoscopic recurrence — information that could affect preoperative assessment and planning for...

This matters because it documents organising pneumonia occurring during biomarker-confirmed UC remission and emphasizes that lung disease in IBD patients may be disease-intrinsic rather than always drug-induced. Expert...

The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...

The study describes a new berberine-containing nanocomplex that reduced inflammation and improved gut barrier function in cell, mouse, and organoid models of ulcerative colitis, suggesting a potential new direction for...

Patient-centered measures help clinics track and improve care experiences important to people with IBD. A validated patient-developed PREM could better reflect patient priorities and support quality improvement in UK IBD...

Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...

Trials testing intestinal ultrasound–guided treat-to-target strategies and late-stage therapies could change how Crohn’s disease is monitored and treated if they show improved outcomes.

This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...

Cure8 could only read part of this source from Frontline Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Infliximab.

Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...

If confirmed, differences between tirzepatide and GLP-1RAs could influence medication choice for people with IBD who need weight-loss or glucose-lowering therapy. Reduced IV steroid use suggests fewer severe flares...

Cure8 found this source from Intestinal research, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Azathioprine, and Immunomodulators. Open the original article for the full...

Microplastics are a widespread environmental exposure that this review links to biological changes relevant to IBD — intestinal barrier damage, microbiome shifts, and immune activation — so patients and clinicians may...

AIP-2 is a pancreas-specific autoimmune condition that commonly co-occurs with IBD, especially ulcerative colitis. Recognizing AIP-2 is important because it may present like acute pancreatitis or a pancreatic mass and...

Obituaries that mention Crohn’s disease can help the IBD community by acknowledging lived experience, caregiving burdens, and directing support to relevant charities. They also humanize long-term disease impact.

The study suggests there may be stage-specific differences in mucosal IgA and IgG plasma cell patterns in UC, which could help researchers understand mucosal immunity changes across active disease, quiescence, and...

The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...

This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...

Phase 3 trials test whether a new oral therapy can induce remission in people with moderate-to-severe ulcerative colitis who have not responded to or cannot tolerate existing treatments. If positive, results could add...

People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...

Knowing which treatment target (symptom control alone versus adding endoscopic and histological remission) leads to better long-term outcomes could change how aggressively clinicians treat ulcerative colitis and what...

This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.

Phase 3 trials test whether a new drug is effective and safe enough to be considered for clinical use. ABX464 is being evaluated as a potential new oral treatment for people with moderate-to-severe ulcerative colitis who...

Intestinal ultrasound can assess IBD inflammation without radiation but interpretation varies by operator. Developing AI tools to measure bowel wall thickness and other features could standardize and speed image...

If confirmed in clinical trials, targeting NAD+ metabolism or removing senescent immune cells could become new approaches to treat ulcerative colitis, especially for patients with severe disease or who do not respond to...

The intestinal barrier changes in inflammation and can alter how oral nanocarriers interact with mucus and epithelium; understanding this is important for designing delivery systems that achieve local therapeutic benefit...

Many people with IBD remain symptomatic even when tests show little or no inflammation; recognising these persistent symptoms as a separate treatment target could improve quality of life. This reframes care to address...

Work participation and sick leave affect daily life, income, and quality of life for people with IBD. Understanding when sick leave is more common can help patients, employers, and clinicians plan support around...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Computer Methods in...

People with IBD (ulcerative colitis or Crohn’s/regional enteritis) may develop vitamin K–related hypoprothrombinemia; this updated label describes when and how vitamin K (phytonadione) is used and emphasizes INR...

Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.

Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.

ITB can closely mimic Crohn’s disease, so this study is relevant because it describes diagnostic test yields and illustrates that targeted TB testing and therapeutic trials of antituberculosis treatment can help...

Researchers and clinicians interested in cross-disease host–microbe interactions may find that an IBD–CRC shared microbial/host signature could have prognostic importance beyond the gut, here in bladder cancer.

The study identifies blood gene-expression patterns linked to response to TNF-alpha inhibitors and highlights overlap between psoriasis and IBD, which could point to shared biomarkers or mechanisms relevant to treatment...

The study raises the possibility that perinatal exposure to nanoplastics could have lasting, sex-specific effects on gut health and make adult offspring more susceptible to intestinal inflammation. This may be relevant...

The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.

This study shows that sodium butyrate, a metabolite produced by gut bacteria, changed brain imaging measures and reduced inflammation in mice with experimental IBD, supporting the idea that gut-derived compounds can...